U.K. Regulator Is First to Approve Merck’s Covid-19 Pill
(Bloomberg) --
Britain's regulator became the first in the world to approve Merck & Co.'s Covid-19 antiviral pill, describing the treatment as safe and effective following a swift review.
The drug, molnupiravir, was authorized for use in people with mild to moderate Covid and at least one risk factor for developing severe illness, the U.K.'s Medicines and Healthcare Products Regulatory Agency said Thursday.
Merck shares rose 2% in premarket U.S. trading.
Boris Johnson's government plans to focus on antiviral treatments while rolling out boosters to bolster immunity levels as winter approaches. The approval extends the U.K.'s record of quick action on Covid clearances after it was the first western nation to give the go-ahead to Pfizer Inc. and BioNTech SE's vaccine last year.
The U.K. has already announced deals to secure two new Covid treatments: 480,000 courses of Merck's pill and 250,000 courses of another antiviral made by Pfizer. Based on the clinical trial data, Merck's treatment is most effective when taken during the early stages of infection, the regulator said.
Coronavirus infections in England reached their highest level yet in October, based on a study published Thursday. While hospitalizations and deaths remained low, the React-1 study led by Imperial College London recorded the highest prevalence of cases since the research began in May 2020. Covid infections among study participants increased to 1.72%, or one in 58 people, more than double the level in the previous month's report.
Covid-19 Infections in England at Highest Level Yet, Study Finds
Merck and its partner Ridgeback Biotherapeutics LP sought emergency use authorization in the U.S. for molnupiravir last month. The U.S. Food and Drug Administration scheduled an advisory committee hearing for Nov. 30, saying it would weigh data on the use of the drug to treat mild-to-moderate cases in high-risk adults.
The European Medicines Agency has begun a rolling review of the company's application for marketing authorization in the European Union.
“As an oral therapeutic, molnupiravir offers an important addition to the vaccines and medicines deployed so far to counter the Covid-19 pandemic,” Dr. Dean Y. Li, executive vice president and president of Merck Research Laboratories, said in a statement Thursday.
Molnupiravir works by introducing errors into viral genetic material that eventually make the pathogen defunct. Some experts have questioned whether and how the drug may also impact growing cells in the human body, potentially raising the risk of birth defects, for example.
Nicholas Kartsonis, senior vice president of clinical research for infectious diseases and vaccines at Merck Research Labs, said in an interview last month that he's been “very impressed” by the drug's safety profile and that it looks “really clean.”
Merck's Covid Pill Changes Drugmaker's Fate After Failed Shots
Molnupiravir has been hailed as a potential breakthrough, as it could be relatively cheap and easy to make, doesn't require infusion and has shown it reduces the risk of hospitalization in a trial.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.